Mapatumumab, A TRAIL Receptor 1 Agonist Antibody, Induces Apoptosis in Bortezomib Resistant Multiple Myeloma.

被引：0
|
作者：
Ghoshal, Pushpankur [1 ]
Chitta, Kasyapa [1 ]
Vujcic, Slavoljub [1 ]
Gaddy, Jacquelyne [1 ]
Miles, Kiersten M. [1 ]
Stein, Leighton [1 ]
Sher, Taimur [1 ]
Lee, Kelvin P. [1 ]
Chanan-Khan, Asher A. [1 ]
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1106 / 1107
页数：2
相关论文
共 50 条
  • [41] A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    Chauhan, D
    Catley, L
    Li, GL
    Podar, K
    Hideshima, T
    Velankar, M
    Mitsiades, C
    Mitsiades, N
    Yasui, H
    Letai, A
    Ovaa, H
    Berkers, C
    Nicholson, B
    Chao, TH
    Neuteboom, STC
    Richardson, P
    Palladino, MA
    Anderson, KC
    CANCER CELL, 2005, 8 (05) : 407 - 419
  • [42] Active Vaccination with DKK1 Induces Protective and Therapeutic Antitumor Immunity In Multiple Myeloma.
    Qian, Jianfei
    Hong, Sungyoul
    Qin, Hong
    Wang, Ji
    Wei, Jinsong
    Zhang, Liang
    Li, Haiyan
    Zheng, Yuhuan
    Lan, Yongshen
    Yang, Jing
    Lu, Yong
    Kwak, Larry W.
    Yi, Qing
    BLOOD, 2010, 116 (21) : 1253 - 1253
  • [43] The role of IL-1 receptor antagonist (IL-1Ra) in multiple myeloma.
    Lust, CE
    Donovan, KA
    Moon-Tasson, LL
    Dahlgren, GR
    Lust, JA
    BLOOD, 2003, 102 (11) : 378B - 378B
  • [44] Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody
    Du, Xing
    Xiang, Laiman
    Mackall, Crystal
    Pastan, Ira
    CLINICAL CANCER RESEARCH, 2011, 17 (18) : 5926 - 5934
  • [45] Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28
    Qiu, YH
    Sun, ZW
    Shi, Q
    Su, CH
    Chen, YJ
    Shi, YJ
    Tao, R
    Ge, Y
    Zhang, XG
    CELLULAR IMMUNOLOGY, 2005, 236 (1-2) : 154 - 160
  • [46] Amplification of 1q21 is associated with poor outcome after treatment with bortezomib in relapsed/refractory multiple myeloma.
    Drach, Johannes
    Sagaster, Verena
    Odelga, Victoria
    Kaufmann, Hannes
    Ackermann, Jutta
    Galhuber, Markus
    Zojer, Niklas
    Kueenburg, Elisabeth
    Zielinski, Christoph
    Wieser, Rotraud
    Ludwig, Heinz
    BLOOD, 2006, 108 (11) : 970A - 971A
  • [47] A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
    Kobayashi, Eiji
    Kishi, Hiroyuki
    Ozawa, Tatsuhiko
    Hamana, Hiroshi
    Nakagawa, Hidetoshi
    Jin, Aishun
    Li, Zhezhu
    Muraguchi, Atsushi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 453 (04) : 798 - 803
  • [48] Conditionally Expressed PU.1 Transactivates TRAIL Gene and Induces Apoptosis in Myeloma Cell Lines
    Ueno, Shikiko
    Tatetsu, Hiro
    Hata, Hiroyuki
    Ilno, Tadafumi
    Niiro, Hiroaki
    Akashi, Koichi
    Tenen, Daniel G.
    Mitsuya, Hiroaki
    Okuno, Yutaka
    BLOOD, 2008, 112 (11) : 592 - 592
  • [49] A Novel Orally Bioavailable Heat Shock Protein 90 Inhibitor Induces Apoptosis and Synergises with Bortezomib in Human Multiple Myeloma
    Khong, Tiffany T.
    Yeh, Sung Lin
    Spencer, Andrew
    BLOOD, 2009, 114 (22) : 730 - 730
  • [50] A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells
    Park, Kyung-Jin
    Lee, Seung-Hyun
    Kim, Tae-In
    Lee, Hae-Won
    Lee, Chang-Han
    Kim, Eun-Hee
    Jang, Ji-Young
    Choi, Kyeong Sook
    Kwon, Myung-Hee
    Kim, Yong-Sung
    CANCER RESEARCH, 2007, 67 (15) : 7327 - 7334
12345